Decitabine and Gemcitabine for Pancreatic Cancer and Sarcoma

Phase 1 Completed 36 enrolled Mohammed Milhem Holden Comprehensive Cancer Center · collab University of Iowa · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this Phase 1b study is to assess the safety and maximum tolerated dose (MTD) of Decitabine in combination with Gemcitabine among previously treated patients diagnosed with advanced pancreatic adenocarcinoma or sarcoma (soft tissue and bone).

Timeline

Start: 2016-12-05
Primary completion: 2019-09-30
Completion: 2020-10-16

Publications

Tost J, Ak-Aksoy S, Campa D, Corradi C, Farinella R, Ibanez-Costa A, Dubrot J, Earl J, Melian EB, Kataki A, Kolnikova G, Madjarov G, Chaushevska M, Strnadel J, Tanic M, Tomas M, Dubovan P, Urbanova M, Buocikova V, Smolkova B. Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications. Semin Cancer Biol. 2025 Feb;109:101-124. doi: 10.1016/j.semcancer.2025.01.003. Epub 2025 Jan 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Decitabine	Small molecule	0.1 mg/kg	Subcutaneous
Subject	Decitabine	Small molecule	0.2 mg/kg	Subcutaneous
Subject	Gemcitabine	Small molecule	900 mg/m2	Intravenous

Decitabine and Gemcitabine for Pancreatic Cancer and Sarcoma

Summary

Timeline

Publications

Drugs

Indications